FRM
CCXI

Fox Run Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Fox Run Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,546
Closed -$214K – 803
2022
Q1 		$214K Buy
+8,546
New +$240K 0.12% 393
2017
Q1 		– Sell
-12,100
Closed -$90K – 793
2016
Q4 		$90K Buy
+12,100
New +$87.1K 0.05% 470

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fox Run Management's CCXI Position: Q2 2022 in Review

Fox Run Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 8,546 shares — an estimated $214K sold.

Fox Run Management first reported a position in CCXI in Q4 2016 and held it in 2 quarters. The position peaked at $214K in Q1 2022. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

  • Fox Run Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
  • Fox Run Management sold 8,546 ChemoCentryx, Inc. shares in Q2 2022, an estimated $214K.
  • Fox Run Management first reported a position in ChemoCentryx, Inc. in Q4 2016 and held it in 2 quarters.
  • Fox Run Management's ChemoCentryx, Inc. position peaked at $214K in Q1 2022.
  • 182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Fox Run Management's 13F filing for Q2 2022, filed 12 Aug 2022.